• 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • Hashimoto S et al a Serial analysis of gene


    Hashimoto, S., et al., 1999a. Serial analysis of gene expression in human monocyte-de-rived dendritic cells. Blood 94, 845–852. Hashimoto, S., et al., 1999b. Serial analysis of gene expression in human monocytes and macrophages. Blood 94, 837–844. Hashimoto, S.I., et al., 2000. Identification of genes specifically expressed in human ac-tivated and mature dendritic cells through serial analysis of gene expression. Blood 96, 2206–2214. Hashimoto, S., et al., 2017. Comprehensive single-cell transcriptome analysis reveals heterogeneity in endometrioid adenocarcinoma tissues. Sci. Rep. 7, 14225.
    Hirohashi, Y., et al., 2010. Immune response against tumor INCB018424 expressed on human cancer stem-like cells/tumor-initiating cells. Immunotherapy 2, 201–211.
    Mariya, T., et al., 2016. Matrix metalloproteinase-10 regulates stemness of ovarian cancer stem-like cells by activation of canonical Wnt signaling and can be a target of che-motherapy-resistant ovarian cancer. Oncotarget 7, 26806–26822. Michifuri, Y., et al., 2012. High expression of ALDH1 and SOX2 diffuse staining pattern of oral squamous cell carcinomas correlates to lymph node metastasis. Pathol. Int. 62, 684–689.
    Visvader, J.E., Lindeman, G.J., 2008. Cancer stem cells in solid tumours: accumulating
    Yasuda, K., et al., 2013. Ovarian cancer stem cells are enriched in side population and
    aldehyde dehydrogenase bright overlapping population. PLoS ONE 8, e68187. Yasuda, K., et al., 2016. MAPK13 is preferentially expressed in gynecological cancer stem
    Yusuf, N., et al., 2014. SPARC was overexpressed in human endometrial cancer stem-like cells and promoted migration activity. Gynecol. Oncol. 134, 356–363.
    Contents lists available at ScienceDirect
    International Journal of Biological Macromolecules
    Cloning, expression of the truncation of recombinant peroxidase derived from millet bran and its reversal effects on 5-Fu resistance in colorectal cancer
    a Key Laboratory of Chemical Biology and Molecular Engineering of National Ministry of Education, Institute of Biotechnology, Shanxi University, Taiyuan, China
    b School of Life Sciences, Shanxi University, Taiyuan, China
    Article history:
    Millet bran peroxidase (FMBP)
    Truncated protein
    5-Fu resistance of colorectal cancer 
    A novel peroxidase (FMBP) was extracted and purified from foxtail millet bran in our previous study and it pos-sessed excellent anti-colon cancer activity both in vitro and in vivo. However, the active fragment of FMBP respon-sible for the anti-colon cancer effects remains unclear. In present, three different truncated sequences of FMBP were designed and cloned into a plasmid vector (pMal-s). Three recombinant segments were successfully expressed in host strain Escherichia coli DH5α induced by IPTG (0.3 mM) at 37 °C for 4 h, respectively named MBP-FMBP-1, MBP-FMBP-2 and MBP-FMBP-3. MTT assay showed that only MBP-FMBP-2 possessed significant anti-colon cancer activity, and its anti-colon cancer activity was equivalent to FMBP. Further, the results showed that MBP-FMBP-2 significantly reversed the 5-Fu resistance in human colorectal cancer HCT-8/Fu cell through inhibiting cell proliferation, promoting cell apoptosis and increasing the intracellular accumulation of 5-Fu. RT-PCR and western blot assays showed that MBP-FMBP-2 also decreased the expression levels of multi-drug resis-tance protein 1 (MRP1), P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). These results indicate that MBP-FMBP-2 is the effective segment of FMBP which exhibits anti-colon cancer activity and has potential as an outstanding chemotherapeutic agent against colon cancer.
    1. Introduction
    Colorectal cancer (CRC) is a common malignant tumor of the diges-tive system in clinical practice. According to 2018 global cancer data sta-tistics, the incidence and mortality of CRC accounted for 10.2% and 9.2% of the total cancer cases [1]. At present, 5-Fluorouracil (5-Fu) remains a commonly used chemotherapeutic drug in CRC treatment [2–4]. Though 5-Fu has improved the survival rate of CRC patients, long-term use of 5-Fu not only leads to drug resistance of CRC but also causes tremendous side effects to patients [5–7]. Recent studies showed that the functional molecules of nature products possessed the activity of overcoming 5-Fu resistance of tumor. Wen et al. found that curcumin reversed 5-Fu resistance of human colon cancer HCT-8/Fu cell through promoting cell apoptosis and down-regulating Heat Shock Protein 27 and P-gp expression [8]. Ravindranathan et al. study showed that oligo-meric proanthocyanidins (OPCs) from grape seed extract overcame the